Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI - European Academy of Allergy and Clinical Immunology that took place in Munich 27th – 29th May 2018.
Noventure participated in this congress to announce its presence in the allergy field thanks to its medical device RHINOSECTAN® intended to control and prevent symptoms of rhinitis and rhinosinusitis, especially those of allergic origin.
EAACI is the Europe’s largest medical association in the field of allergy and clinical immunology and it offers a unique chance to learn about latest discovery as it gathers KOLs from around the world.
Noventure was present with a shared stand with Diater, thus having a great opportunity for knowledge exchange and networking both with healthcare professionals and potential distributors for Rhinosectan® in EU and worldwide.
RHINOSECTAN® is a class I medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE, Noventure SL)
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.